Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Medix Biochemica Launches MedixMAB by Design™ at AACC 2013

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
Highest quality recombinant antibody production service to ensure superior IVD tests.

Medix Biochemica announces the launch of its MedixMAB by Design™ antibody production service, at the annual AACC meeting in Houston, USA, 28 July – 1 August, 2013 (Booth 3606). Offering a completely customised service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design presents an excellent foundation for superior IVD assays. With antibodies produced to the strictest international quality standards, the new service equips IVD manufacturers with a competitive advantage, helping to increase sales revenue without the need to invest in costly production facilities and expertise.

The advanced production technology of the MedixMAB by Design service allows for the targeting of a broader range of antigens than possible in vivo, including poorly immunoreactive and toxic compounds, and recombinant MAB production is possible on a range of scales (mg-kg). As an alternative to producing full length MABs, Fab fragments can instead be generated in just three months, to greatly enhance specificity and sensitivity of an IVD assay in solid-phase applications. In addition to producing novel antibodies, existing antibodies can also be optimised, for example by humanisation, biotinylation or affinity maturation, for enhanced IVD test performance. Flexibility is an inherent feature of the MedixMAB by Design service, and a personal project manager provides full consultation and support throughout the process, tailoring the service to each individual need.

With the MedixMAB by Design service, high affinity recombinant antibodies exhibiting low cross-reactivity are produced using an advanced in vitro system, which incorporates the latest in cutting-edge phage display antibody production technology. To ensure the highest quality, the entire process is comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and FDA QSR quality standards. Furthermore, the in vitro production system yields a consistent level of quality between batches.

Product manager for MedixMAB by Design, Maija Partanen, commented: “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!